Please login to the form below

Not currently logged in
Email:
Password:

Genzyme’s Richard Moscicki joins FDA

Provides regulatory agency with more than 20 years of industry experience

FDA, Richard MoscickiThe US Food and Drug Administration (FDA) has appointed Genzyme's Dr Richard Moscicki to the newly created position of deputy centre director for science operations at its Center for Drug Evaluation and Research (CDER).

Dr Moscicki, who currently serves as senior VP, head of clinical development at Sanofi's Genzyme division, will help lead the CDER in its role to regulate over-the-counter and prescription-only drugs available in the US.

The FDA will benefit from his strong industry background in research, which includes time spent as medical director and chief medical officer at Genzyme.

He also gained regulatory and pharmacovigilance experience at the US-based biotech, serving as its senior VP of biomedical and regulatory affairs from 1996 to 2011.

In his role at the FDA, Dr Moscicki will work with Dr Bob Temple, deputy director for clinical science, and Dr Doug Throckmorton, deputy director for regulatory programmes.

14th February 2013

From: Research, Regulatory

Share

Tags

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
SEVEN STONES COLLECTIVE

Hello. We are the Total Health creative agency. It’s our collective mix of talent that gets us to truly different...

Latest intelligence

Top-10 Reasons Why You Should be Adding Asynchronous Virtual Touchpoints Between Your Real-time Meetings
...
Flu
Influenza – the risk to vulnerable populations
Why we can't get complacent about flu vaccination...
dementia
Alzheimer’s Research UK highlights socio-economic inequalities in dementia risk
The charity aims to improve the number of women participating in dementia research and grow awareness of dementia risk factors...